Glasdegib is an oral, selective HH inhibitor that binds SMO (112) Clinical trials have been limited to the study of its effect of myeloid malignancies: Japanese phase I NCT 02038777 (99), US and Europe phase I NCT 00953758 (98) and a study in myelofibrosis (NCT 02226172). Here, SMO is linked to myelofibrosis.